{"nctId":"NCT02259127","briefTitle":"ODYSSEY (PENTA 20)","startDateStruct":{"date":"2016-09-20","type":"ACTUAL"},"conditions":["HIV Infection"],"count":792,"armGroups":[{"label":"SOC arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard of Care"]},{"label":"DTG arm","type":"EXPERIMENTAL","interventionNames":["Drug: Dolutegravir"]}],"interventions":[{"name":"Dolutegravir","otherNames":["DTG"]},{"name":"Standard of Care","otherNames":["SOC"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nALL PATIENTS:\n\n* Children ≥28 days and \\<18 years weighing ≥3kg with confirmed HIV-1 infection\n* Parents/carers and children, where applicable, give informed written consent\n* Girls aged 12 years or older who have reached menses must have a negative pregnancy test at screening and be willing to adhere to effective methods of contraception if sexually active\n* Children with co-infections who need to start ART can be enrolled into ODYSSEY according to local/national guidelines\n* Parents/carers and children, where applicable, willing to adhere to a minimum of 96 weeks' follow-up\n\n  * Children weighing 3 to \\<14kg must be eligible and willing to participate in the Weight band (WB)-Pharmacokinetics (PK)1 substudy unless direct enrolment for the child's weight band has opened following the WB-PK1 substudy and/or dosing information has become available from the IMPAACT P1093 DTG dose-finding study.\n\nADDITIONAL CRITERIA FOR ODYSSEY A:\n\n• Planning to start first-line ART\n\nADDITIONAL CRITERIA FOR ODYSSEY B:\n\n* Planning to start second-line ART defined as either: (i) switch of at least 2 ART drugs due to treatment failure; or (ii) switch of only the third agent due to treatment failure where drug sensitivity tests show no mutations conferring Nucleoside Reverse Transcriptase Inhibitor (NRTI) resistance\n* Treated with only one previous ART regimen. Single drug substitutions for toxicity, simplification, changes in national guidelines or drug availability are allowed\n* At least one NRTI with predicted preserved activity available for a background regimen\n* In settings where resistance tests are routinely available, at least one new active NRTI from tenofovir disoproxil fumarate, abacavir or zidovudine should have preserved activity based on cumulative results of resistance tests\n* In settings where resistance tests are not routinely available, children who are due to switch according to national guidelines should have at least one new NRTI predicted to be available from tenofovir disoproxil fumarate, abacavir or zidovudine\n* Viral load ≥ 500 c/ml at screening visit\n\nExclusion Criteria:\n\n* History or presence of known allergy or contraindications to dolutegravir\n* History or presence of known allergy or contraindications to proposed available NRTI backbone or proposed available SOC third agent.\n* Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal, OR ALT ≥3x upper limit of normal and bilirubin ≥2x upper limit of normal\n* Patients with severe hepatic impairment or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)\n* Anticipated need for Hepatitis C virus (HCV) therapy during the study\n* Pregnancy or breastfeeding\n* Evidence of lack of susceptibility to integrase inhibitors or more than a 2-week exposure to antiretrovirals of this class","healthyVolunteers":false,"sex":"ALL","minimumAge":"28 Days","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Difference in Proportion With Failure (Clinical or Virological)","description":"Treatment failure by 96 weeks.\n\nEstimated using time to the first occurrence of any of the following components:\n\n* Insufficient virological response defined as \\< 1 log10 drop at week 24 and switch to second/third line ART for treatment failure\n* Viral Load (VL)\\>400 c/ml at or after 36 weeks confirmed by next visit\n* Death due to any cause\n* Any new or recurrent AIDS defining event (WHO 4) or severe WHO 3 events, adjudicated by the Endpoint Review Committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"16","spread":null},{"groupId":"OG004","value":"10","spread":null},{"groupId":"OG005","value":"26","spread":null},{"groupId":"OG006","value":"30","spread":null},{"groupId":"OG007","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"HIV-1 RNA <50c/ml at 96 Weeks","description":"Proportion of children with viral load suppression \\<50 c/ml at 96 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"270","spread":null},{"groupId":"OG001","value":"252","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"117","spread":null},{"groupId":"OG005","value":"113","spread":null},{"groupId":"OG006","value":"153","spread":null},{"groupId":"OG007","value":"139","spread":null}]}]}]},{"type":"SECONDARY","title":"HIV-1 RNA <400c/mL at 96 Weeks","description":"Proportion of children with viral load suppression \\<400 c/ml at 96 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":null},{"groupId":"OG001","value":"285","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"26","spread":null},{"groupId":"OG004","value":"129","spread":null},{"groupId":"OG005","value":"124","spread":null},{"groupId":"OG006","value":"170","spread":null},{"groupId":"OG007","value":"161","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in CD4 Count From Baseline to Week 96","description":"Reporting mean change from the global baseline value across both arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":"17"},{"groupId":"OG001","value":"230","spread":"17"},{"groupId":"OG002","value":"72","spread":"116"},{"groupId":"OG003","value":"51","spread":"118"},{"groupId":"OG004","value":"311","spread":"23"},{"groupId":"OG005","value":"267","spread":"24"},{"groupId":"OG006","value":"228","spread":"24"},{"groupId":"OG007","value":"202","spread":"24"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Total Cholesterol From Baseline to Week 96","description":"Reporting mean change from global baseline value across both arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"1.5"},{"groupId":"OG001","value":"9.9","spread":"1.5"},{"groupId":"OG002","value":"4.5","spread":"5.6"},{"groupId":"OG003","value":"29.6","spread":"5.9"},{"groupId":"OG004","value":"2.1","spread":"2.3"},{"groupId":"OG005","value":"19.6","spread":"2.3"},{"groupId":"OG006","value":"-10.5","spread":"1.8"},{"groupId":"OG007","value":"2.8","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Events","description":"Incidence of serious adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"23","spread":null},{"groupId":"OG005","value":"27","spread":null},{"groupId":"OG006","value":"12","spread":null},{"groupId":"OG007","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Grade 3 or Above Clinical and Laboratory Adverse Events","description":"Incidence of new clinical and laboratory grade 3 and 4 adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"21","spread":null},{"groupId":"OG004","value":"48","spread":null},{"groupId":"OG005","value":"43","spread":null},{"groupId":"OG006","value":"25","spread":null},{"groupId":"OG007","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events Leading to ART Modification Any Grade","description":"Incidence of adverse events (of any grade) leading to treatment modification","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"8","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Failure by 48 Weeks","description":"Treatment failure by 48 weeks. Difference in proportion with clinical or virological failure (as defined above)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"9","spread":null},{"groupId":"OG007","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"5","spread":null},{"groupId":"OG005","value":"5","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Failure by 144 Weeks","description":"Treatment failure by 144 weeks. Difference in proportion with clinical or virological failure (as defined above)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"28","spread":null},{"groupId":"OG004","value":"35","spread":null},{"groupId":"OG005","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"WHO 4, Severe WHO 3 Events and Death","description":"Rate of clinical events : WHO 4, severe WHO 3 events and death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"6","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Per Protocol: Treatment Failure by 96 Weeks","description":"Per protocol: treatment failure by 96 weeks post randomisation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"20","spread":null},{"groupId":"OG004","value":"13","spread":null},{"groupId":"OG005","value":"28","spread":null},{"groupId":"OG006","value":"31","spread":null},{"groupId":"OG007","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Any Drug Class Resistance After Virologic Failure","description":"Any drug class resistance after virologic failure 96 weeks post randomisation\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"36","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"12","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"NRTI Resistance After Virologic Failure","description":"NRTI resistance after virologic failure 96 weeks post randomisation.\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"31","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"10","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"NNRTI Resistance After Virologic Failure","description":"NNRTI resistance after virologic failure 96 weeks post randomisation.\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"36","spread":null},{"groupId":"OG004","value":"6","spread":null},{"groupId":"OG005","value":"11","spread":null},{"groupId":"OG006","value":"2","spread":null},{"groupId":"OG007","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"PI Resistance After Virologic Failure","description":"PI resistance after virologic failure 96 weeks post randomisation.\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"INSTI Resistance After Virologic Failure","description":"INSTI resistance after virologic failure 96 weeks post randomisation\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Emerging Resistance to Any Drug Class After Virologic Failure","description":"Emerging resistance to any drug class after virologic failure 96 weeks post randomisation\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.\n\n\\>=14kg cohort: among participants with virologic failure and exposure to the drug class, percentage of participants with emerging resistance was estimated under an assumption of the same proportion of new resistance in participants with an available baseline resistance test and those without.\n\n\\<14kg cohort: percentage reported for participants with whom resistance test was available post-failure and at baseline, and exposed to drug-class during trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"19","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"NRTI Emerging Resistance After Virologic Failure","description":"NRTI emerging resistance after virologic failure 96 weeks post randomisation\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.\n\n\\>=14kg cohort: among participants with virologic failure and exposure to the drug class, percentage of participants with emerging resistance was estimated under an assumption of the same proportion of new resistance in participants with an available baseline resistance test and those without.\n\n\\<14kg cohort: percentage reported for participants with whom a resistance test was available post-failure and at baseline, and exposed to drug-class during trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"10","spread":null},{"groupId":"OG005","value":"100","spread":null},{"groupId":"OG006","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"NNRTI Emerging Resistance After Virologic Failure","description":"NNRTI emerging resistance after virologic failure 96 weeks post randomisation\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.\n\n\\>=14kg cohort: among participants with virologic failure and exposure to the drug class, percentage of participants with emerging resistance was estimated under an assumption of the same proportion of new resistance in participants with an available baseline resistance test and those without.\n\n\\<14kg cohort: percentage reported for participants with whom a resistance test was available post-failure and at baseline, and exposed to drug-class during trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"PI Emerging Resistance After Virologic Failure","description":"PI emerging resistance after virologic failure 96 weeks post randomisation\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.\n\n\\>=14kg cohort: among participants with virologic failure and exposure to the drug class, percentage of participants with emerging resistance was estimated under an assumption of the same proportion of new resistance in participants with an available baseline resistance test and those without.\n\n\\<14kg cohort: percentage reported for participants with whom a resistance test was available post-failure and at baseline, and exposed to drug-class during trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"INSTI Emerging Resistance After Virologic Failure","description":"INSTI emerging resistance after virologic failure 96 weeks post randomisation\n\nMajor International AIDS Society (IAS) drug-resistance mutations were defined according to the 2019 update of the IAS drug-resistance mutations.\n\n\\>=14kg cohort: among participants with virologic failure and exposure to the drug class, percentage of participants with emerging resistance was estimated under an assumption of the same proportion of new resistance in participants with an available baseline resistance test and those without.\n\n\\<14kg cohort: percentage reported for participants with whom a resistance test was available post-failure and at baseline, and exposed to drug-class during trial.\n\nThe integrase gene was not sequenced for the standard of care arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Any New or Recurrent AIDS Defining Event (WHO 4) or Severe WHO 3 Events","description":"Time to any new or recurrent AIDS defining event (WHO 4) or severe WHO 3 events adjudicated by the Endpoint Review Committee.\n\nReported in \\>=14kg and \\<14kg papers. \\>=14kg cohort paper (https://www.nejm.org/doi/full/10.1056/NEJMoa2108793) \\<14kg cohort paper (https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00163-1/fulltext)","classes":[]},{"type":"SECONDARY","title":"Adherence Questionnaire","description":"The proportion of adherence questionnaires where the participant/carer reports missing a dose within the last week will be compared between randomised groups.\n\nReported in \\>=14kg and \\<14kg papers. \\>=14kg cohort paper (https://www.nejm.org/doi/full/10.1056/NEJMoa2108793) \\<14kg cohort paper (https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00163-1/fulltext)","classes":[]},{"type":"SECONDARY","title":"Health-related Quality of Life Questionnaire","description":"Adapted from the Euro Quality of Life Questionnaire (Qol)-5D questionnaire The EQ5D-3L (3-level version of EQ-5D) questionnaire contains five questions about the participants' quality of life: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.\n\nEach question has three dimensions: no problems, some problems, and extreme problems.\n\nThis analysis reports whether the participant reports any problems (some or extreme). Percentages are of participants completing at least one EQ5D-3L questionnaire during follow-up.\n\nReported in \\>=14kg cohort paper (https://www.nejm.org/doi/full/10.1056/NEJMoa2108793)","classes":[]},{"type":"SECONDARY","title":"Acceptability Questionnaire","description":"Number of participants reported to have problems with size, taste or swallowing of the medicines as assessed by Acceptability questionnaire\n\nReported in \\>=14kg and \\<14kg papers. \\>=14kg cohort paper (https://www.nejm.org/doi/full/10.1056/NEJMoa2108793) \\<14kg cohort paper (https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00163-1/fulltext)","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change in Weight From Baseline","description":"Mean change in weight from baseline to week 96","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"0.3"},{"groupId":"OG001","value":"6.1","spread":"0.3"},{"groupId":"OG002","value":"5.0","spread":"0.2"},{"groupId":"OG003","value":"5.1","spread":"0.2"},{"groupId":"OG004","value":"7.8","spread":"0.4"},{"groupId":"OG005","value":"6.5","spread":"0.4"},{"groupId":"OG006","value":"6.7","spread":"0.3"},{"groupId":"OG007","value":"5.9","spread":"0.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change in BMI-for-age Z-score From Baseline","description":"Mean change in BMI-for-age from baseline to week 96. Reporting mean change from the global baseline value across both arms.\n\nz-scores (standard scores) are the number of standard deviations the observed data is above or below the population (z-score of 0 represents the population median). Positive z-scores represent the standard deviations above the median and negative z-scores represent the standard deviations below the median. BMI-for-age Z scores indicate: \\<-3SD severe thinness; \\<-2SD thinness; -2 to 1SD healthy weight; \\>1SD overweight; \\>2SD obese.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.04"},{"groupId":"OG001","value":"0.11","spread":"0.04"},{"groupId":"OG002","value":"1.1","spread":"0.3"},{"groupId":"OG003","value":"1.5","spread":"0.3"},{"groupId":"OG004","value":"0.36","spread":"0.07"},{"groupId":"OG005","value":"0.20","spread":"0.07"},{"groupId":"OG006","value":"0.14","spread":"0.05"},{"groupId":"OG007","value":"0.04","spread":"0.05"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":350},"commonTop":[]}}}